Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 29300-269

10 FDA label images from Unichem Pharmaceuticals (usa), Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 29300-269). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (269f0768 2e6c 4188 Ba86 2d7420d31a21 01)

Structural Formula (269f0768 2e6c 4188 Ba86 2d7420d31a21 01)
Chemical structure of Rizatriptan Benzoate, showing its molecular components and connections.*
FDA Label Image

Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4 (269f0768 2e6c 4188 Ba86 2d7420d31a21 02)

Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4 (269f0768 2e6c 4188 Ba86 2d7420d31a21 02)
A line graph showing the estimated probability of response over time (hours post-dose) for Rizatriptan Benzoate Tablets, USP 5 mg, 10 mg, and placebo. The x-axis represents hours post-dose from 0 to 2, and the y-axis shows estimated probability of response as a percentage from 0% to 100%. Three lines with different markers represent placebo (square), 5 mg (triangle), and 10 mg (inverted triangle) doses, with both doses showing higher response probabilities than placebo over time.*
FDA Label Image

Estimated Probablity Of Remedication Or Response Vs. Hrs Post-dose For Rizatriptan Tablets (269f0768 2e6c 4188 Ba86 2d7420d31a21 03)

Estimated Probablity Of Remedication Or Response Vs. Hrs Post-dose For Rizatriptan Tablets (269f0768 2e6c 4188 Ba86 2d7420d31a21 03)
A line graph depicting the estimated probability of remediation or rescue over 24 hours post-dose for Rizatriptan Benzoate Tablets, USP 5 mg and 10 mg, compared to placebo. The graph shows three lines representing placebo, 5 mg, and 10 mg doses, with probability percentages on the y-axis and hours post-dose on the x-axis.*
FDA Label Image

Estimated Probablity Of Response Vs. Hrs Post-dose For Rizatriptan Odt (269f0768 2e6c 4188 Ba86 2d7420d31a21 04)

Estimated Probablity Of Response Vs. Hrs Post-dose For Rizatriptan Odt (269f0768 2e6c 4188 Ba86 2d7420d31a21 04)
A line graph depicting the estimated probability of response over 2 hours post-dose for Rizatriptan Benzoate Orally Disintegrating Tablets at 5 mg and 10 mg doses compared to placebo. The x-axis represents hours post-dose (0 to 2), and the y-axis shows the estimated probability of response (%) from 0% to 100%. The 10 mg dose shows the highest response probability, followed by the 5 mg dose, with placebo the lowest.*
FDA Label Image

Estimated Probablity Of Remedication Of Rescue Vs. Hrs Post-dose For Rizatriptan Odt (269f0768 2e6c 4188 Ba86 2d7420d31a21 05)

Estimated Probablity Of Remedication Of Rescue Vs. Hrs Post-dose For Rizatriptan Odt (269f0768 2e6c 4188 Ba86 2d7420d31a21 05)
A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose for Rizatriptan Benzoate Orally Disintegrating Tablets USP at 5 mg and 10 mg strengths compared to placebo. The x-axis indicates hours post-dose (0 to 24), and the y-axis shows the probability percentage (0% to 100%). Three lines represent placebo, 5 mg dose, and 10 mg dose, each with distinct dash styles.*
FDA Label Image

Observed Percentage Versus Hours Post Stage 2 Dose (269f0768 2e6c 4188 Ba86 2d7420d31a21 06)

Observed Percentage Versus Hours Post Stage 2 Dose (269f0768 2e6c 4188 Ba86 2d7420d31a21 06)
A line graph comparing Rizatriptan Benzoate Orally Disintegrating Tablets, USP to placebo. The x-axis shows Hours Post Stage 2 Dose (0.5 to 2.0 hours) and the y-axis shows Percent (95% CI) from 0 to 100. The graph shows increasing percent values over time for both Rizatriptan Benzoate and placebo, with Rizatriptan Benzoate consistently higher throughout the time points.*
FDA Label Image

Company Logo (269f0768 2e6c 4188 Ba86 2d7420d31a21 07)

FDA Label Image

Company Logo (269f0768 2e6c 4188 Ba86 2d7420d31a21 08)

FDA Label Image

Carton 5 mg (269f0768 2e6c 4188 Ba86 2d7420d31a21 09)

Carton 5 mg (269f0768 2e6c 4188 Ba86 2d7420d31a21 09)
Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP, 5 mg. The label indicates the product is an oral disintegrating tablet with a strength of 5 mg. It is labeled for prescription use only and manufactured by Unichem Pharmaceuticals (USA), Inc. The label also includes instructions to dispense with patient information, package details, and storage warnings.*
FDA Label Image

Carton 10 mg (269f0768 2e6c 4188 Ba86 2d7420d31a21 10)

Carton 10 mg (269f0768 2e6c 4188 Ba86 2d7420d31a21 10)
Box label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP, 10 mg strength. The label indicates the package contains 18 orally disintegrating tablets in 6 blister strips of 3 tablets each. It is labeled for prescription use only and manufactured by Unichem Pharmaceuticals (USA), Inc. The label includes storage instructions, barcode, and warning to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.